Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin - Université Clermont Auvergne Accéder directement au contenu
Article Dans Une Revue Neuropharmacology Année : 2018

Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin

Laura Poupon
  • Fonction : Auteur
Sylvain Lamoine
  • Fonction : Auteur
Vanessa Pereira
David Barriere
  • Fonction : Auteur
Stéphane Lolignier
Youssef Aissouni
Mathieu Meleine
Laetitia Prival
  • Fonction : Auteur
Damien Richard Richard
Nicolas Kerckhove
Nicolas Authier
David Balayssac
Alain Eschalier
  • Fonction : Auteur
Jérôme Busserolles

Résumé

Neurotoxicity remains the most common adverse effect of oxaliplatin, limiting its clinical use. In the present study, we developed a mouse model of chronic oxaliplatin-induced neuropathy, which mimics both sensory and motor deficits observed in patients, in a clinically relevant time course. Repeated oxaliplatin administration in mice induced both cephalic and extracephalic long lasting mechanical and cold hypersensitivity after the first injection as well as delayed sensorimotor deficits and a depression-like phenotype. Using this model, we report that riluzole prevents both sensory and motor deficits induced by oxaliplatin as well as the depression-like phenotype induced by cumulative chemotherapeutic drug doses. All the beneficial effects are due to riluzole action on the TREK-1 potassium channel, which plays a central role in its therapeutic action. Riluzole has no negative effect on oxaliplatin antiproliferative capacity in human colorectal cancer cells and on its anticancer effect in a mouse model of colorectal cancer. Moreover, riluzole decreases human colorectal cancer cell line viability in vitro and inhibits polyp development in vivo. The present data in mice may support the need to clinically test riluzole in oxaliplatin-treated cancer patients and state for the important role of the TREK-1 channel in pain perception.
Fichier principal
Vignette du fichier
Poupon_Targeting_TREK-1_CombinedAAM.pdf (1.71 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-02065469 , version 1 (05-12-2023)

Identifiants

Citer

Laura Poupon, Sylvain Lamoine, Vanessa Pereira, David Barriere, Stéphane Lolignier, et al.. Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin. Neuropharmacology, 2018, 140, pp.43-61. ⟨10.1016/j.neuropharm.2018.07.026⟩. ⟨hal-02065469⟩
93 Consultations
38 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More